# Biomarker Core

> **NIH NIH P30** · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · 2021 · $304,582

## Abstract

ABSTRACT – BIOMARKER CORE
The primary objective of the newly configured Biomarker Core (BC) is to collect, bank, and distribute biofluids in
order to generate biomarker datasets that will address disease heterogeneity and clinical transitions to subjective
cognitive decline (SCD), mild cognitive impairment (MCI) and early stages of Alzheimer's disease (AD), with the
long term goal of developing novel interventions that will delay or prevent these transitions. During its more than
25 years of continued funding, the NYU ADRC has been in the forefront of improving diagnostic tools and defining
preclinical and prodromal stages of AD. In this renewal period, the dedicated BC will be reconfigured to serve as
a conceptual and technical core for established investigators and the next generation of students and
neuroscientists; and, to foster the use of plasma, serum and cerebrospinal fluid (CSF), as well as stool samples
for microbiome analyses, to understand biological mechanisms of disease progression and heterogeneity. We
propose the following Aims. In Aim 1, we will coordinate intake, processing and storage of biofluids from Clinical
Core (CC) participants in association with the Data Management & Statistics (DMS) Core. In Aim 2, we will
perform state-of-the-art analysis of known blood and CSF biomarkers for the diagnosis, prognosis, and prediction
of AD. Assays will include, but will not be limited to, Aβ40/42/38, phosphorylated/total tau and neurofilament
light-chain, all within the new amyloid/tau/neurodegeneration (ATN) framework, in addition to markers of
cerebrovascular disease, inflammation, glial activation, as well as biological variables such as age, sex, ApoE4,
and sleep (among others), which will be key to increase our understanding of disease heterogeneity. In Aim 3,
we will use Simoa technology to develop novel ultrasensitive biomarker assays, guided in part by proteomic
findings by the Neuropathology (NP) Core and other emerging data from the ADRC network. Aim 4 is designed
to manage samples, perform quality control and analyses as well as link sample information obtained through
the DMS, CC, Neuroimaging (NIC), and NP Cores. As part of Aim 5, we will share biosamples with NCRAD and
other research collaborative efforts within NYU (e.g. NYU Metabolomics Lab) and outside collaborators from
other ADRC (e.g. Microbiome Project). Last, in Aim 6, we will collaborate with other ADRCs to harmonize and
optimize biomarker assays across centers. In summary, the BC will perform state-of-the-art biofluid biomarker
analyses within the new ATN framework, and work with the NIC and CC cores to help understand disease
heterogeneity and stage transitions to SCD, MCI, and AD. Further, it will help harmonize multiple biomarker
assays and develop scientific discovery of novel ultrasensitive biomarkers for AD.

## Key facts

- **NIH application ID:** 10148613
- **Project number:** 5P30AG066512-02
- **Recipient organization:** NEW YORK UNIVERSITY SCHOOL OF MEDICINE
- **Principal Investigator:** THOMAS M WISNIEWSKI
- **Activity code:** P30 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2021
- **Award amount:** $304,582
- **Award type:** 5
- **Project period:** 2020-05-01 → 2025-04-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10148613

## Citation

> US National Institutes of Health, RePORTER application 10148613, Biomarker Core (5P30AG066512-02). Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/grant/nih/10148613. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*